Meyer S - Search Results

1

Promoter methylation of aminopeptidase N/CD13 in malignant melanoma.

Wulfänger J, Schneider H, Wild P, Ikenberg K, Rodolfo M, Rivoltini L, Meyer S, Riemann D, Seliger B. Wulfänger J, et al. Among authors: meyer s. Carcinogenesis. 2012 Apr;33(4):781-90. doi: 10.1093/carcin/bgs091. Epub 2012 Feb 3. Carcinogenesis. 2012. PMID: 22307972

2

Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma.

Wulfänger J, Biehl K, Tetzner A, Wild P, Ikenberg K, Meyer S, Seliger B. Wulfänger J, et al. Among authors: meyer s. Int J Cancer. 2013 Dec 1;133(11):2522-32. doi: 10.1002/ijc.28278. Epub 2013 Jun 14. Int J Cancer. 2013. PMID: 23686552

3

Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma.

Roesch A, Becker B, Meyer S, Hafner C, Wild PJ, Landthaler M, Vogt T. Roesch A, et al. Among authors: meyer s. Mod Pathol. 2005 Apr;18(4):565-72. doi: 10.1038/modpathol.3800324. Mod Pathol. 2005. PMID: 15502804 Free article.

4

HER3 is a determinant for poor prognosis in melanoma.

Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A. Reschke M, et al. Among authors: meyer s. Clin Cancer Res. 2008 Aug 15;14(16):5188-97. doi: 10.1158/1078-0432.CCR-08-0186. Clin Cancer Res. 2008. PMID: 18698037 Free article.

5

A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.

Meyer S, Fuchs TJ, Bosserhoff AK, Hofstädter F, Pauer A, Roth V, Buhmann JM, Moll I, Anagnostou N, Brandner JM, Ikenberg K, Moch H, Landthaler M, Vogt T, Wild PJ. Meyer S, et al. PLoS One. 2012;7(6):e38222. doi: 10.1371/journal.pone.0038222. Epub 2012 Jun 7. PLoS One. 2012. PMID: 22685558 Free PMC article.

6

Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma.

Meyer S, Handke D, Mueller A, Biehl K, Kreuz M, Bukur J, Koehl U, Lazaridou MF, Berneburg M, Steven A, Massa C, Seliger B. Meyer S, et al. Cancers (Basel). 2021 Aug 3;13(15):3907. doi: 10.3390/cancers13153907. Cancers (Basel). 2021. PMID: 34359808 Free PMC article.

7

Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas.

Roesch A, Becker B, Meyer S, Wild P, Hafner C, Landthaler M, Vogt T. Roesch A, et al. Among authors: meyer s. Mod Pathol. 2005 Sep;18(9):1249-57. doi: 10.1038/modpathol.3800413. Mod Pathol. 2005. PMID: 15803180 Free article.

8

Identification of new genes associated with melanoma.

Mauerer A, Roesch A, Hafner C, Stempfl T, Wild P, Meyer S, Landthaler M, Vogt T. Mauerer A, et al. Among authors: meyer s. Exp Dermatol. 2011 Jun;20(6):502-7. doi: 10.1111/j.1600-0625.2011.01254.x. Epub 2011 Mar 16. Exp Dermatol. 2011. PMID: 21410771

9

Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.

Meyer S, Wild PJ, Vogt T, Bataille F, Ehret C, Gantner S, Landthaler M, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK. Meyer S, et al. Exp Dermatol. 2010 Aug;19(8):e251-7. doi: 10.1111/j.1600-0625.2010.01072.x. Exp Dermatol. 2010. PMID: 20500769 Free article.

10

Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma.

Rothhammer T, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, Hein R, Hofstaedter F, Bosserhoff AK. Rothhammer T, et al. Among authors: meyer s. Cancer Biomark. 2007;3(2):111-7. doi: 10.3233/cbm-2007-3205. Cancer Biomark. 2007. PMID: 17522432

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,202 results

Search Page

Filters